Uncategorized
Intel Says It Won’t Even Make $500M From Gaudi AI Chips In 2024 Despite Nvidia Minting Billions: CEO Gelsinger Says Uptake ‘Slower Than We Anticipated’
Intel has a Gaudi problem on its hands – the chipmaker revealed that its AI accelerator won’t even make $500 million in 2024. read more
Apple, Microsoft Need To Do More Than Just Beating Wall Street Estimates, Says Analyst: ‘AI Enthusiasm And Potential Is Not Enough”
The comment comes at a time when companies like Microsoft, Apple and Meta are banking on the AI buzz. read more
Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy
ESSA Pharma terminates its Phase 2 masofaniten trial in prostate cancer after interim data shows no added efficacy over enzalutamide alone, shifting focus to other priorities. read more
LyondellBasell Q3 Results Miss Estimates, Signals Softer Demand And Rising Costs For Q4
LYB shares down after reporting Q3 results below expectations. Higher feedstock costs and seasonality may impact Q4. read more
JPMorgan To Pay Investors $151 Million After SEC Flags ‘Various Law Violations’
The SEC charged JPMorgan in five separate enforcement actions for failures including misleading disclosures to investors. read more
Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
Novo Nordisk’s ESSENCE trial of semaglutide 2.4 mg shows significant improvements in liver fibrosis and steatohepatitis outcomes, with regulatory filings planned for 2025. read more
Top 3 Energy Stocks That Are Preparing To Pump In November
Latest Ratings for BORR Date Firm Action From To Jun 2020 Citigroup Maintains Neutral Apr 2020 BTIG Downgrades Buy Neutral Mar 2020 Citigroup Maintains Neutral View More Analyst Ratings for BORR View the Latest Analyst Ratings read more